
SENATE BILL 6105

State of Washington

65th Legislature

2018 Regular Session

By Senators Ranker, Cleveland, Darneille, Keiser, Nelson, Wellman, Dhingra, McCoy, Lias, Carlyle, Frockt, Hunt, Palumbo, Kuderer, Hasegawa, and Mullet

Prefiled 01/05/18. Read first time 01/08/18. Referred to Committee on Health & Long Term Care.

1 AN ACT Relating to enacting the reproductive health access for
2 all act; adding a new section to chapter 41.05 RCW; and creating a
3 new section.

4 BE IT ENACTED BY THE LEGISLATURE OF THE STATE OF WASHINGTON:

5 NEW SECTION. **Sec. 1.** A new section is added to chapter 41.05
6 RCW to read as follows:

7 (1) The authority shall administer a program to reimburse the
8 cost of medically appropriate services, drugs, devices, products, and
9 procedures for individuals who can become pregnant and who would be
10 eligible for medical assistance if not for 8 U.S.C. Sec. 1611 or
11 1612.

12 (2) The authority shall collect data and analyze the cost-
13 effectiveness of the services, drugs, devices, products, and
14 procedures paid for under this section.

15 (3) The authority shall explore any and all opportunities to
16 obtain federal financial participation in the costs of implementing
17 this section including, but not limited to, waivers or demonstration
18 projects under Title X of the public health service act or Title XIX
19 or XXI of the social security act. However, the implementation of
20 this section is not contingent upon the authority's receipt of a
21 waiver or authorization to operate a demonstration project.

1 (4) For purposes of this section, "medically appropriate
2 services, drugs, devices, products, and procedures" include:

3 (a) Well-woman care, including screenings, assessments, and
4 counseling;

5 (b) Counseling for sexually transmitted infections, including but
6 not limited to human immunodeficiency virus and acquired
7 immunodeficiency syndrome;

8 (c) Screening for:

9 (i) Chlamydia;

10 (ii) Gonorrhoea;

11 (iii) Hepatitis B;

12 (iv) Hepatitis C;

13 (v) Human immunodeficiency virus and acquired immunodeficiency
14 syndrome;

15 (vi) Human papillomavirus;

16 (vii) Syphilis;

17 (viii) Anemia;

18 (ix) Urinary tract infection;

19 (x) Pregnancy;

20 (xi) Rh incompatibility;

21 (xii) Gestational diabetes;

22 (xiii) Osteoporosis;

23 (xiv) Breast cancer; and

24 (xv) Cervical cancer;

25 (d) Screening to determine whether counseling related to the
26 BRCA1 or BRCA2 genetic mutations is indicated and counseling related
27 to the BRCA1 or BRCA2 genetic mutations if indicated;

28 (e) Screening and appropriate counseling or interventions for:

29 (i) Tobacco use; and

30 (ii) Domestic and interpersonal violence;

31 (f) Folic acid supplements;

32 (g) Abortion;

33 (h) Breastfeeding comprehensive support, counseling, and
34 supplies;

35 (i) Breast cancer chemoprevention counseling;

36 (j) Any contraceptive drug, device, or product approved by the
37 United States food and drug administration, subject to all of the
38 following:

39 (i) If there is a therapeutic equivalent of a contraceptive drug,
40 device, or product approved by the United States food and drug

1 administration, the authority may provide coverage for either the
2 requested contraceptive drug, device, or product or for one or more
3 therapeutic equivalents of the requested drug, device, or product.

4 (ii) If a contraceptive drug, device, or product covered by the
5 authority is deemed medically inadvisable by the individual's
6 provider, the authority must cover an alternative contraceptive drug,
7 device, or product prescribed by the provider.

8 (iii) The authority must provide coverage without a prescription
9 for all contraceptive drugs available for over-the-counter sale that
10 are approved by the United States food and drug administration.

11 (iv) The authority may not infringe upon an individual's choice
12 of contraception and may not require prior authorization, step
13 therapy, or other utilization control techniques for covered
14 contraceptive drugs, devices, or other products approved by the
15 United States food and drug administration;

16 (k) Voluntary sterilization;

17 (l) Patient education and counseling on contraception and
18 sterilization;

19 (m) Services related to sterilization or the administration and
20 monitoring of contraceptive drugs, devices, and products including,
21 but not limited to:

22 (i) Management of side effects;

23 (ii) Counseling for continued adherence to a prescribed regimen;

24 (iii) Device insertion and removal; and

25 (iv) Provision of alternative contraceptive drugs, devices, or
26 products deemed medically appropriate in the judgment of an
27 individual's provider;

28 (n) Any additional preventive services for women that must be
29 covered without cost sharing as identified by the United States
30 preventive services task force or the health resources and services
31 administration of the United States department of health and human
32 services.

33 NEW SECTION. **Sec. 2.** This act may be known and cited as the
34 reproductive health access for all act.

--- END ---